News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Call for Roche to lower Kadcyla price further after NICE rej... Ruling could end funding for cancer drug in England.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
News Pfizer looks to confirm US licence for breast cancer pill Pfizer has filed late stage data with FDA.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
